Jie Wang

Assistant Professor of Medicine

Medicine, Hematological Malignancies

jie.wang416@duke.edu

Box 3961 Med Ctr, Durham, NC 27710

Hematologic Malignancies, Box 3961 DUMC, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education
2. Training & Certifications

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition

Professional Activities

Embed Profile Data

Embed Profile Data

Selected Grants

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms

Clinical TrialPrincipal Investigator · Awarded by University of Michigan · 2024 - 2029

Regeneron: III:REGN1979: A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 × ANTI-CD3BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (D

Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2029

HCRN-LYM21-544

Clinical TrialPrincipal Investigator · Awarded by Hoosier Cancer Research Network, Inc · 2024 - 2027

Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma (Valemetostat tosylate [DS-3201b], an enhancer of zeste homolog [EZH] 1/2 dual inhibitor, for R/R PTCL)

Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2022 - 2027

: A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF DS-3201B IN SUBJECTS WITH LYMPHOMAS

Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2021 - 2026

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigators Choice in Patients with Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) PTCL-001

Clinical TrialPrincipal Investigator · Awarded by University of Virginia - Charlottesville · 2024 - 2025

A Phase I, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

Clinical TrialPrincipal Investigator · Awarded by MacroGenics, Inc. · 2019 - 2024

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) PTCL-001

Clinical TrialPrincipal Investigator · Awarded by University of Virginia - Charlottesville · 2024 - 2024